Literature DB >> 222469

Cellular regulation of mammalian sarcoma virus expression: a gene regulation model for oncogenesis.

K J Porzig, K C Robbins, S A Aaronson.   

Abstract

Investigations aimed at defining cellular functions required for expression of transformation by mammalian sarcoma viruses have led to the isolation of a class of revertants that contain biologically active feline sarcoma virus, yet possess in vitro and in vivo properties of normal cells. The block to expression of the transformed state in these cellular revertants was spontaneously reversible at low frequency. Moreover, infection with certain helper viruses reversed the block at very high efficiency. Helper virus complementation was shown not to be a direct effect of helper virus functions expressed in the initially infected revertant cell. Rather, the helper virus acted indirectly by rescuing sarcoma virus and allowing it to infect and transform another cell within the revertant population. Using biochemical and immunologic techniques, it was possible to demonstrate a specific and very marked reduction in transcriptional and translational products of the sarcoma viral genome in the revertant cells. Findings that the reversal of this block was associated with reacquisition of the transformed phenotype, together with other evidence, suggest that reversion results from cellular transcriptional regulation of the integrated sarcoma virus genome. Reversion in this virus transformation system provides a model for oncogenesis resulting from derepression of cellular genes that possess malignant potential.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222469     DOI: 10.1016/0092-8674(79)90102-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  11 in total

1.  High-frequency changes in transcriptional activity in polyomavirus-transformed cell lines.

Authors:  L Bouchard; F Mathieu; M Bastin
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

2.  Expression of Kirsten murine sarcoma virus in transformed nonproducer and revertant NIH/3T3 cells: evidence for cell-mediated resistance to a viral oncogene in phenotypic reversion.

Authors:  J D Norton; F Cook; P C Roberts; J P Clewley; R J Avery
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

3.  Frequent hereditable shutdown of murine retrovirus gene expression in murine cell lines.

Authors:  R K Bestwick; C A Machida; E Polonoff; D Kabat
Journal:  Mol Cell Biol       Date:  1984-05       Impact factor: 4.272

4.  Revertants and partial transformants of rat fibroblasts infected with Fujinami sarcoma virus.

Authors:  B Mathey-Prevot; M Shibuya; J Samarut; H Hanafusa
Journal:  J Virol       Date:  1984-05       Impact factor: 5.103

5.  Origin and functional properties of the major gene product of the Snyder-Theilen strain of feline sarcoma virus.

Authors:  M Barbacid; K Beemon; S G Devare
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Transformation-defective mutants of feline sarcoma virus which express a product of the viral src gene.

Authors:  L Donner; L P Turek; S K Ruscetti; L A Fedele; C J Sherr
Journal:  J Virol       Date:  1980-07       Impact factor: 5.103

7.  Lack of focus formation of S+L- mink cells by the ecotropic murine leukemia viral genome.

Authors:  A Ishimoto
Journal:  J Virol       Date:  1980-10       Impact factor: 5.103

8.  Transformation-defective mutants of Snyder-Theilen feline sarcoma virus lack tyrosine-specific protein kinase activity.

Authors:  M Barbacid; L Donner; S K Ruscetti; C J Sherr
Journal:  J Virol       Date:  1981-07       Impact factor: 5.103

9.  Cellular transformation by subgenomic feline sarcoma virus DNA.

Authors:  M Barbacid
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

10.  Involvement of a high-molecular-weight polyprotein translational product of Snyder-Theilen Feline sarcoma virus in malignant transformation.

Authors:  F H Reynolds; W J Van de Ven; J Blomberg; J R Stephenson
Journal:  J Virol       Date:  1981-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.